Karim Galzahr left the role of Director at OS Therapies Inc. As of November 6, 2026, OS Therapies Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 2, 2026 to October 5, 2026, naming 1 appointment and 1 departure (Form 8-K, July 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like OS Therapies Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
OS Therapies Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-02 to 2026-10-05. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as OS Therapies Inc files it.
Also on the record for OS Therapies Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 23, 2026 | Form D, private offering | $7.17M sold | Form D page | Source |
| August 25, 2026 | Form D, private offering | $5M sold | Form D page | Source |
| July 16, 2026 | Form D, private offering | $1.60M sold | Form D page | Source |
| March 6, 2026 | Form D, private offering | $2M sold | Form D page | Source |
| January 20, 2026 | Form D, private offering | $3.50M sold | Form D page | Source |
| September 10, 2025 | Form D, private offering | $3.78M sold | Form D page | Source |
| August 18, 2025 | Stake report, Schedule 13D/A, by Shalom Auerbach | 8.5% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G/A, by Thomas A. Satterfield, Jr. | 9.4% of the class | 5%+ stakes | Source |
| July 16, 2025 | Form D, private offering | $4.22M sold | Form D page | Source |
| January 22, 2025 | Form D, private offering | $7.10M sold | Form D page | Source |
Selling to them or working with them? See who runs OS Therapies Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on OS Therapies Inc and the records around it.
OS Therapies Inc elsewhere on the record
- Company profile and every filing Oct 2026
- Form D filing Oct 2026
- Form D filing Aug 2026
- 5%+ stake filings Aug 2025
- Who owns it
Companies that share a holder
- Thomas A. Satterfield, Jr. also filed stake reports on 8 other companies: Lantern Pharma Inc. (Jul 2026), Curis, Inc. (May 2026), enVVeno Medical Corporation (Nov 2025)
Watch OS Therapies Inc
Get an email when OS Therapies Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on OS Therapies Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on OS Therapies Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on OS Therapies Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-05 | Reported | not named in the filing | 8-K, 2026-10-05 | ||
| 2026-07-02 | Out | Director | 8-K, 2026-07-02 | ||
| 2026-07-02 | In | Director | 8-K, 2026-07-02 |
Who leads OS Therapies Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Karim Galzahr, departure reported (filed 2026-07-02). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on OS Therapies Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch OS Therapies Inc (free up to 3)
Find people with the same kind of experience as the Director at OS Therapies Inc, with the record behind each one.
Find candidates like Director at OS Therapies IncEvery change, in the filing's words
Reported
Effective September 29, 2026, the Board of Directors of OS Therapies Incorporated (the "Company") appointed Francis (Frank) Knuettel II to serve as Chief Financial Officer of the Company and Kerry Clem to serve as Chief Commercial Officer of the Company.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- In connection with Mr. Knuettel's appointment, Christopher P. Acevedo ceased serving as Chief Financial Officer of the Company and will continue to provide services to the Company in a consulting capacity.
- Frank Knuettel II, CFO Frank Knuettel II, 60, brings more than three decades of executive leadership experience with early-stage public companies in the technology and life sciences sectors.
- From June 2022 through July 2025, Mr. Knuettel served as Chief Financial Officer of Channel Therapeutics Corporation (formerly NYSE American: CHRO), a developer of non-opioid pain therapeutics, and, beginning in July 2023, also served as Chief Executive Officer.
- Following Channel's merger with LNHC, Inc. and the subsequent change of Channel's name to Pelthos Therapeutics Inc. (NYSE American: PTHS) in July 2025, Mr. Knuettel served as Chief Financial Officer of Pelthos, a biopharmaceutical company focused on commercializing innovative, safe and efficacious therapeutic products to address unmet treatment needs, until April 2026.
- Prior to that, from December 2020 to March 2022, he served as Chief Executive Officer of Unrivaled Brands, Inc. (formerly OTCQX: UNRV), a California-based operator of cannabis assets.
Departing: Karim Galzahr, Director
On June 1, 2026, Karim Galzahr notified the Company of his resignation from the Company's board of directors, effective immediately.
Appointed: Craig Eagle, Director
On June 1, 2026, the Company's board of directors appointed Dr. Craig Eagle to the board of directors to fill the vacancy created by Mr. Galzahr's resignation, effective immediately.
- Mr. Galzahr's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Dr. Eagle currently serves in an advisory capacity to the Company as its Chief Medical Advisor.
- Dr. Eagle has served as Chief Medical Officer of Guardant Health, Inc. (Nasdaq: GH) since May 2021.
- From 2019 to May 2021, he served as Vice President, Medical Affairs Oncology at Genentech, where he was responsible for medical programs across the oncology portfolio and supported the development of clinical trial strategies in personalized medicine.
- Prior to Genentech, Dr. Eagle spent approximately 10 years at Pfizer Inc. in a series of senior leadership roles, including Oncology Business Lead for the United Kingdom and Canada, Global Lead for Oncology Strategic Alliances and Partnerships, and Global Head of the Oncology Therapeutic Area Global Medical and Outcomes Group, where he also oversaw the U.S. oncology business.
- Dr. Eagle received his medical degree from the University of New South Wales in Sydney, Australia and completed his internal medicine training at Royal North Shore Hospital in Sydney.
OS Therapies Inc's funding history
Tools for this story
Each opens in a new tab, filled in for OS Therapies Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.